Showcases Stock ranks Forex

Affimed N.V. (AFMD)
3.28  -0.02 (-0.61%) 08-08 16:00
Open: 3.34 Pre. Close: 3.3
High: 3.4 Low: 3.22
Volume: 737,761 Market Cap: 490M
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia; and AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. Affimed N.V. has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; and Roivant Sciences Ltd., as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 3.403 - 3.42 3.42 - 3.431
Low: 3.18 - 3.202 3.202 - 3.216
Close: 3.248 - 3.282 3.282 - 3.303
Stock Technical Analysis
Target: Six months: 3.97
One year: 4.64
Support: Support1: 2.97
Support2: 2.70
Resistance: Resistance1: 3.40
Resistance2: 3.97
Pivot: 3.02
Moving Averages: MA(5): 3.12
MA(20): 3.00
MA(100): 3.38
MA(250): 4.71
MACD: MACD(12,26): 0.06
Signal(12,26,9): 0.02
%K %D: %K(14,3): 93.21
%D(3): 78.54
RSI: RSI(14): 61.08
52-Week: High: 7.35
Low: 2.23
Change(%): -44.1
Average Vol(K): 3-Month: 1041
10-Days: 676
Price, MAs and Bollinger Bands
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.

[ AFMD ] has closed below upper band by 10.9%. Bollinger Bands are 16.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
Stock chart
Stock News
Mon, 08 Aug 2022
AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Lags Revenue Estimates - Nasdaq

Fri, 05 Aug 2022
Affimed (AFMD) to Release Earnings on Thursday - MarketBeat

Wed, 03 Aug 2022
Should You Buy Affimed NV (AFMD) Stock After it Is Down 3.59% in a Week? - InvestorsObserver

Tue, 26 Jul 2022
Affimed (NASDAQ:AFMD) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

Thu, 30 Jun 2022
Affimed Establishes Scientific Advisory Board - GlobeNewswire

Fri, 10 Jun 2022
Affimed Presents Preclinical Data of Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA) - GlobeNewswire

Financial Analysis
Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange:  NASDAQ Global Market
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 149.32
Shares Float (M) 101.45
% Held by Insiders 3.40
% Held by Institutions 60.80
Shares Short (K) 4450
Shares Short Prior Month (K) 3980
Stock Financials
EPS -0.659
Book Value (p.s.) 0.950
Profit Margin -197.47
Operating Margin -201.00
Return on Assets (ttm) -20.7
Return on Equity (ttm) -52.8
Qtrly Rev. Growth -29.8
Gross Profit (p.s.) 0.280
Sales Per Share 0.256
EBITDA (p.s.) -0.511
Qtrly Earnings Growth
Operating Cash Flow (M) -98.98
Levered Free Cash Flow (M) -47.96
Stock Valuation
PE Ratio -4.98
PEG Ratio
Price to Book value 3.45
Price to Sales 12.79
Price to Cash Flow -4.95
Stock Dividends
Dividend Yield
Dividend Growth

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android